Cristalline and amorphous form of a triazolo (4,5-d) pyridimine compound

Abstract

The invention provides new forms of a chemical compound of formula (I). The invention relates to forms fo a chemical compound (I), in particular to crystalline and amorphous forms, more particularly four crystalline forms and an amorphous form. The invention further relates to processes for the preparation of such forms, to pharmaceutical compositions comprising the compound in crystalline and/or amorphous form and to therapeutic use of such forms.

1 - 32 . (canceled)  
     
     
         33 . A compound of formula (I):  
       
         
           
           
               
               
           
         
         selected from:  
         a compound of formula (I) characterised by an X-ray powder diffraction pattern containing specific peaks of high intensity at 5.3° (±0.1°), 20.1° (±0.1°), 20.7° (±0.10), 21.0° (±0.1 ) and 21.3° (±0.1°) 2θ;  
         a compound of formula (I) characterised by an X-ray powder diffraction pattern containing specific peaks of high intensity at 5.5° (±0.1°), 13.5° (±0.1°), 18.3° (±0.1°), 22.7° (±0.1°) and 24.3° (±0.1°) 2θ;  
         a compound of formula (I) characterised by an X-ray powder diffraction pattern containing specific peaks of high intensity at 14.0° (±0.1°), 17.4° (±0.1°), 18.4° (±0.1°), 21.4° (±0.1°) and 24.1° (±0.1°) 2θ; and  
         a compound of formula (I) characterised by an X-ray powder diffraction pattern containing specific peaks of high intensity at 4.9° (±0.1°), 9.2° (±0.1°), 11.6° (±0.1°), 15.6°(±0.1°) and 16.4° (±0.1°) 2θ, wherein said compound of formula (I) exists in an amorphous form.  
       
     
     
         34 . A compound of formula (I) in a substantially amorphous form.  
     
     
         35 . A compound of formula (I) as claimed in  claim 33  which is in the form of a hydrate.